Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

NCT00005831 ·Status: COMPLETED ·Phase: PHASE2

Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

NCT05038657 ·Status: UNKNOWN ·Phase: PHASE2

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT04887831 ·Status: TERMINATED ·Phase: PHASE2

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

NCT03785925 ·Status: COMPLETED ·Phase: PHASE2

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965 ·Status: RECRUITING ·Phase: PHASE3

Intervention of Bladder Cancer by CAR-T

NCT03185468 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

NCT06567743 ·Status: RECRUITING ·Phase: PHASE2

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

NCT04917809 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

NCT03915405 ·Status: TERMINATED ·Phase: PHASE1

Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

NCT02169284 ·Status: TERMINATED ·Phase: PHASE2

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

NCT00004856 ·Status: TERMINATED ·Phase: PHASE2

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503 ·Status: COMPLETED ·Phase: PHASE2

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

NCT06877676 ·Status: APPROVED_FOR_MARKETING

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

NCT02535650 ·Status: UNKNOWN ·Phase: PHASE2

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

NCT06167356 ·Status: RECRUITING

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT02844816 ·Status: COMPLETED ·Phase: PHASE2

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02657486 ·Status: COMPLETED ·Phase: NA

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

NCT05567185 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

NCT03404791 ·Status: COMPLETED ·Phase: PHASE1

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

NCT00066352 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820 ·Status: RECRUITING ·Phase: PHASE3

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201 ·Status: COMPLETED ·Phase: PHASE2